OakChart

Lineage Cell Therapeutics Inc

LCTXHealthcare·Biotechnology·USA·Micro·AMEX·Nov 11 • 1:32 PM ET

1.11+0.07 (6.25%)
2026-11-11 19:33 CET
Market cap
263.02 USD m
Revenue, TTM
13.08 USD m
Net income, TTM
-32.26 USD m
Free cash flow, TTM
-24.39 USD m
EPS diluted, TTM
-0.18
P/E
-
Compare

Price

LCTX against its 20, 50 and 200-day averages
2050200beatearnings
1.001.201.401.6011.3M22.5MMay 26Jun 26Jul 26Aug 26Sep 26Oct 26Nov 26LCTXclose 1.1120-day 1.0150-day 1.00200-day 1.301.1152w low

44.5% under the 52-week high of 1.99 on 13 Nov 2025. 52-week low 0.88 on 1 Oct 2026. Last 15 sessions, 19.1% high to low

Profile

LCTX
52-week range, 21% of the way up
0.881.99

Lineage Cell Therapeutics, Inc. is a clinical-stage biotechnology company developing cell replacement therapies to treat serious medical conditions. The company's pipeline consists of seven allogeneic cell transplant therapy programs spanning clinical to research stages, targeting a range of conditions including dry-AMD, spinal cord injuries, auditory neuropathy, Type 1 Diabetes, and vision loss, with several programs supported by strategic partnerships with Roche, Genentech, William Demant Invest, and Factor Biosciences. The company was founded by Judith Segall, Hal Sternberg, Paul E. Segall and Harold D. Waitz on November 30, 1990 and is headquartered in Carlsbad, CA.

IndexRUT
Employees77
IPOMar 05, 1992
Beta1.68
ATR, 14d0.06
Rel volume1.20
Short float12.74%
Insider own24.46%
Inst own26.72%

Snapshot

6 groups

Valuation

IndexRUT
Market Cap279.46M
Enterprise Value229.81M
Income-32.26M
Sales13.08M
Book/sh0.24
Cash/sh0.20
Dividend Est.-
Dividend TTM-
Dividend Ex-Date-
Dividend Gr. 3/5Y- -
Payout-
Employees77
IPOMar 05, 1992

Ratios

P/E-
Forward P/E-
PEG-
P/S21.37
P/B4.59
P/C5.50
P/FCF-
EV/EBITDA-
EV/Sales17.57
Quick Ratio6.61
Current Ratio6.61
Debt/Eq0.04
LT Debt/Eq0.02
Option/ShortYes / Yes

Earnings

EPS (ttm)-0.18
EPS next Y-0.10
EPS next Q-0.03
EPS this Y79.08%
EPS next Y-65.86%
EPS next 5Y-
EPS past 3/5Y-21.30% -14.94%
Sales past 3/5Y-0.33% 79.88%
EPS Y/Y TTM23.17%
Sales Y/Y TTM19.87%
EPS Q/Q77.21%
Sales Q/Q-61.34%
EarningsNov 12 AMC
EPS/Sales Surpr.-6.01% -41.97%

Ownership

Insider Own24.46%
Insider Trans0.00%
Inst Own26.72%
Inst Trans2.44%
ROA-32.75%
ROE-59.03%
ROIC-51.81%
Gross Margin93.81%
Oper. Margin-205.23%
Profit Margin-246.58%
SMA209.38%
SMA5010.03%
SMA200-15.13%
Trades-

Technical

Shs Outstand252.91M
Shs Float191.06M
Short Float12.74%
Short Ratio18.72
Short Interest24.35M
52W High1.99 -44.47%
52W Low0.88 25.24%
Volatility6.39% 6.07%
ATR (14)0.06
RSI (14)61.13
Beta1.68
Rel Volume1.20
Avg Volume1.30M
Volume1,000,578

Performance

Perf Week7.28%
Perf Month21.66%
Perf Quarter4.25%
Perf Half Y-13.67%
Perf YTD-33.83%
Perf Year-39.29%
Perf 3Y6.25%
Perf 5Y-55.08%
Perf 10Y-59.49%
Recom1.43
Target Price5.50
Prev Close1.04
Price1.11
Change %6.25%

Analyst ratings

latest 6 of 6
DateActionAnalystRating changeTargetImplied
Apr 28, 2026InitiatedCCanaccord GenuityBuy$9+714.5%
Aug 20, 2024InitiatedCCraig HallumBuy$4+262.0%
Nov 02, 2022InitiatedRRobert W. BairdOutperform$5+352.5%
Jun 14, 2022InitiatedRB. Riley SecuritiesBuy$4+262.0%
Aug 19, 2021InitiatedNNoble Capital MarketsOutperform$8+624.0%
Mar 31, 2021InitiatedCCantor FitzgeraldOverweight$6+443.0%

Peers

Mkt cap
TickerCompanyMkt cap
IPSCCentury Therapeutics Inc310.04M
NGENNervGen Pharma Corp144.21M
CAPRCapricor Therapeutics Inc613.94M
IRDOpus Genetics Inc366.90M
MESOMesoblast Ltd ADR1.80B
OCGNOcugen Inc323.29M
SANASana Biotechnology Inc693.02M
ANNXAnnexon Inc788.67M
FATEFate Therapeutics Inc199.98M
EYPTEyePoint Inc31.62M

Insider trading

1 filings
InsiderRelationshipDateTransactionCostSharesValueTotal heldForm
Culley Brian MPresident and CEOMar 12 '26Buy1.6215,00024,375255,516Mar 12 04:05 PM

Held by

AUM
TickerCompanyAUM
VTIVanguard Morningstar Total Stock Market ETFAUM: 687.42B
IWMiShares Russell 2000 Index FundAUM: 77.38B
VXFVanguard Extended Market Index ETFAUM: 30.47B
IWOiShares Russell 2000 Growth ETFAUM: 14.06B
IBBiShares Biotechnology ETFAUM: 11.36B
VTWOVanguard Russell 2000 Index ETFAUM: 16.75B
IWCiShares Micro-Cap ETFAUM: 1.22B
GSSCGoldman Sachs ActiveBeta U.S. Small Cap Equity ETFAUM: 1.06B
BUSMEA Bridgeway Ultra-Small Company Market ETFAUM: 111.21M
VTWGVanguard Russell 2000 Growth Index ETFAUM: 1.41B

News

latest 14 of 200

Quarterly earnings

actual against estimate
PeriodReportedEPS actEPS estEPS repSales actSales estAnalysts
2026Q32026-11-12--0.029--2.327
2026Q22026-08-06-0.030-0.028-0.0301.071.846
2026Q12026-05-12-0.030-0.020-0.0271.733.607
2025Q42026-03-050.004-0.0430.0046.601.977
2025Q32025-11-06-0.130-0.026-0.1303.682.307
2025Q22025-08-12-0.130-0.027-0.1332.771.476
2025Q12025-05-13-0.020-0.026-0.0181.501.727
2024Q42025-03-10-0.020-0.030-0.0152.901.626
2024Q32024-11-14-0.020-0.040-0.0163.781.036
2024Q22024-08-08-0.030-0.045-0.0311.410.946
2024Q12024-05-09-0.040-0.038-0.0361.441.366
2023Q42024-03-07-0.030-0.043-0.0282.102.647
2023Q32023-11-09-0.040-0.042-0.0411.252.606
2023Q22023-08-10-0.030-0.044-0.0313.232.207
2023Q12023-05-11-0.030-0.038-0.0262.392.215
2022Q42023-03-09-0.030-0.040-0.0371.902.577

Annual earnings

PeriodEPS actEPS estEPS repSales actSales est
2019FY-0.080-0.123-0.0813.523.31
2020FY-0.140-0.198-0.1381.832.40
2021FY-0.260-0.158-0.2624.344.01
2022FY-0.150-0.151-0.15514.7015.35
2023FY-0.120-0.144-0.1248.959.55
2024FY-0.090-0.110-0.0939.508.18
2025FY-0.280-0.296-0.28014.569.90
2026FY--0.059--15.16
2027FY--0.097--19.70
2028FY-0.032--59.78
2029FY-0.198--124.47
2030FY-1.160--505.42

Estimate revisions

last 14 periods
PeriodTypeDateEstimatesUpDownMeanLowHigh
2026Q3S2026-10-216002.321.077.50
2026Q3S2026-09-236042.321.077.50
2026Q3S2026-08-075041.281.071.70
2026Q3S2026-08-065002.551.355.56
2026Q3S2026-07-275002.551.355.56
2026Q3S2026-05-215222.551.355.56
2026Q3S2026-05-206232.711.355.56
2026Q3S2026-05-136242.711.355.56
2026Q3S2026-05-016223.651.356.61
2026Q3S2026-04-276314.901.3510.97
2026Q3S2026-03-065315.161.3510.97
2026Q3S2026-02-045004.400.848.57
2026Q3S2026-01-215104.400.848.57
2026Q3S2025-11-215204.400.848.57

Estimate history

EPS, annual-0.17-0.362-0.081-0.138-0.262-0.155-0.124-0.093-0.276-0.1844
Period201720182019202020212022202320242025TTM
EPS, quarterly-0.031-0.016-0.015-0.018-0.133-0.130.004-0.027-0.03
PeriodQ2 '24Q3 '24Q4 '24Q1 '25Q2 '25Q3 '25Q4 '25Q1 '26Q2 '26
Sales, annual3.4581.4161.4780.7733.89614.7038.9459.49914.55613.08
Period201720182019202020212022202320242025TTM
Sales, quarterly1.4083.7792.8681.5022.7653.6816.6081.7251.069
PeriodQ2 '24Q3 '24Q4 '24Q1 '25Q2 '25Q3 '25Q4 '25Q1 '26Q2 '26
Shares, annual126.866127.136149.804153.096169.477170.093174.987220.416243.122252.907
Period201720182019202020212022202320242025MRQ
Shares, quarterly188.824188.837220.416228.356228.356230.328243.122249.298252.907
PeriodQ2 '24Q3 '24Q4 '24Q1 '25Q2 '25Q3 '25Q4 '25Q1 '26Q2 '26

Income statement, annual

Currency USD, millions
MetricTTM2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY
Total Revenue13.0814.569.508.9514.703.900.771.481.42
Cost of Goods Sold Incl. D&A0.810.840.941.361.462.302.423.413.58
Gross Profit12.2713.718.567.5813.251.60-1.65-1.93-2.16
Selling, General and Administrative Excl. Other39.1235.4930.0332.3135.7751.2525.1533.8842.41
Research and Development20.5217.7312.4515.5713.8433.7011.1015.9518.76
Other Operating Expense0.000.000.000.000.000.000.000.000.00
Operating Income-26.85-21.78-21.48-24.73-22.52-49.66-26.80-35.81-44.57
Unusual Expense13.5050.58-2.120.171.971.574.66-7.368.75
Net Income Before Taxes-37.38-68.65-18.58-23.28-25.81-43.27-21.92-19.23-47.13
Income Taxes-5.28-5.280.00-1.800.540.00-1.24-7.41-0.35
Consolidated Net Income-32.10-63.37-18.58-21.48-26.35-43.27-20.68-11.83-46.78
Net Income From Continuing Operations-32.26-63.53-18.61-21.49-26.27-43.02-20.65-11.71-45.99
Net Income-32.26-63.53-18.61-21.49-26.27-43.02-20.65-11.71-45.99
EPS (Recurring)-0.13-0.12-0.10-0.12-0.15-0.25-0.12-0.12-0.31
EPS (Basic, Before Extraordinaries)-0.14-0.28-0.09-0.12-0.15-0.26-0.14-0.08-0.36
EPS (Diluted)-0.18-0.28-0.09-0.12-0.15-0.26-0.14-0.08-0.36
EBITDA-26.11-21.08-20.87-24.04-21.79-48.77-24.69-32.68-41.29
Non-Operating Income (Expense)2.973.710.781.62-1.327.969.539.226.18
Other After Tax Adjustments0.000.000.000.000.000.000.000.000.00
Stock Option Compensation Expense4.073.755.083.673.393.521.632.614.27
Price To Sales Ratio26.1826.4010.5921.0413.51103.45341.6387.6381.82
Gross Margin93.8194.1990.0784.7690.1040.99-213.58-130.85-152.47
Operating Margin-205.23-149.62-226.11-276.50-153.17-1,274.54-3,467.01-2,423.07-3,147.39
Net Margin-246.58-436.47-195.90-240.20-178.69-1,104.18-2,671.28-792.22-3,247.88
Shares Outstanding252.91243.12220.42174.99170.09169.48153.10149.80127.14
Market Capitalization263.02263.02110.76190.74198.87412.97263.98133.32115.92

Income statement, quarterly

Currency USD, millions
Metric2026Q22026Q12025Q42025Q32025Q22025Q12024Q42024Q3
Total Revenue1.071.736.613.682.771.502.873.78
Cost of Goods Sold Incl. D&A0.190.190.250.180.210.200.300.18
Gross Profit0.881.546.363.502.561.302.563.60
Selling, General and Administrative Excl. Other9.809.1312.907.287.507.817.677.44
Research and Development4.774.238.243.273.113.113.423.17
Other Operating Expense0.000.000.000.000.000.000.000.00
Operating Income-8.92-7.59-6.55-3.79-4.94-6.50-5.11-3.84
Unusual Expense-9.44-2.35-1.2626.5527.58-2.30-2.140.01
Net Income Before Taxes1.54-4.79-4.39-29.75-30.36-4.14-3.25-3.00
Income Taxes0.000.00-5.280.000.000.000.000.00
Consolidated Net Income1.54-4.790.89-29.75-30.36-4.14-3.25-3.00
Net Income From Continuing Operations1.48-4.810.85-29.78-30.46-4.14-3.27-3.03
Net Income1.48-4.810.85-29.78-30.46-4.14-3.27-3.03
EPS (Recurring)-0.06-0.03-0.00-0.05-0.05-0.03-0.02-0.02
EPS (Basic, Before Extraordinaries)0.01-0.020.00-0.13-0.13-0.02-0.01-0.02
EPS (Diluted)-0.03-0.030.00-0.13-0.13-0.02-0.01-0.02
EBITDA-8.74-7.41-6.36-3.61-4.77-6.34-4.96-3.70
Non-Operating Income (Expense)1.020.460.900.582.160.06-0.280.84
Other After Tax Adjustments0.000.000.000.000.000.000.000.00
Stock Option Compensation Expense1.601.170.101.201.241.221.311.33
Price To Sales Ratio26.1827.9227.8935.7618.9910.6811.6619.61
Gross Margin82.5189.1096.1995.0392.4186.6889.3795.26
Operating Margin-834.71-440.17-99.09-102.85-178.66-433.09-178.17-101.61
Net Margin138.63-278.9612.88-809.05-1,101.77-275.57-114.12-80.29
Shares Outstanding252.91249.30243.12230.33228.36228.36220.42188.84
Market Capitalization263.02393.56384.65385.92207.21103.13110.76170.95

Balance sheet, annual

Currency USD, millions
Metric2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY2017FY
Cash & Short Term Investments55.7847.8035.4957.8858.3641.6430.7231.0938.17
Short Term Receivables1.560.640.740.3051.140.5024.743.723.05
Inventories0.000.000.000.000.000.000.000.000.00
Other Current Assets1.812.552.201.832.051.852.061.551.40
Total Current Assets59.1651.0038.4460.00111.5544.0057.5236.3642.62
Net Property, Plant & Equipment4.704.394.775.674.875.638.185.835.53
Total Investments and Advances0.530.560.550.580.540.520.1056.30117.17
Intangible Assets42.3757.2157.2357.3657.4957.7058.923.126.90
Deferred Tax Assets5.80--------
Other Assets0.030.050.030.050.100.100.760.041.02
Total Assets112.58113.22101.02123.66174.54107.95125.48101.66173.24
Short Term Debt Incl. Current Port. of LT Debt0.851.150.880.950.830.761.220.310.36
Accounts Payable2.341.172.052.393.542.612.432.360.94
Other Current Liabilities8.1711.6515.0315.6442.744.402.844.155.58
Total Current Liabilities11.3713.9817.9618.9847.127.776.496.816.88
Long Term Debt1.571.362.072.941.972.543.941.960.15
Provision for Risks Charges0.000.000.000.000.000.000.000.000.00
Deferred Tax Liabilities0.020.270.272.082.082.083.31--
Other Liabilities56.2820.5918.6927.7332.480.440.480.641.95
Total Liabilities69.2436.2139.0051.7383.6512.8214.239.418.98
Non-Equity Reserves0.000.000.000.000.000.000.000.000.00
Preferred Stock - Carrying Value0.000.000.000.000.000.000.000.000.00
Common Equity44.5578.3863.4273.3492.2296.20112.9693.84162.64
Total Shareholders Equity44.5578.3863.4273.3492.2296.20112.9693.84162.64
Accumulated Minority Interest-1.20-1.37-1.40-1.40-1.32-1.07-1.71-1.591.62
Total Equity43.3577.0162.0271.9490.9095.13111.2592.25164.26
Total Liabilities & Stockholders Equity112.58113.22101.02123.66174.54107.95125.48101.66173.24
Book Value Per Share0.180.360.360.430.540.630.750.741.28
Tangible Book Value Per Share0.010.100.040.090.200.250.360.711.23
Full-Time Employees777775786155557995
Price to Book Ratio4.321.432.802.524.502.801.181.241.26
Return on Assets-56.27-17.37-19.13-17.62-30.46-17.69-10.31-33.46-12.65
Return on Equity-103.36-26.25-31.42-31.74-45.66-19.74-11.32-35.86-14.24
Return on Invested Capital-137.77-23.34-32.81-34.44-45.67-20.91-10.02-48.01-12.27
Quick Ratio5.203.652.143.162.375.668.865.346.20
Current Ratio5.203.652.143.162.375.668.865.346.20

Cash flow, annual

Currency USD, millions
MetricTTM2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY
Net Income-32.26-63.53-18.61-21.49-26.27-43.02-20.65-11.71-45.99
Depreciation0.740.700.610.690.730.892.113.133.27
Other Funds (Non Cash)16.9653.303.674.837.90-2.52-2.52-21.2811.20
Funds from Operations-19.84-14.81-14.33-17.76-17.64-44.66-21.05-29.86-31.52
Extraordinary Item0.000.000.000.000.000.000.000.000.00
Changes in Working Capital-3.97-4.11-8.77-10.8018.7021.101.30-2.080.64
Cash from Operating Activities-23.82-18.92-23.09-28.571.06-23.56-19.75-31.95-30.88
Capital Expenditures-0.57-0.52-0.56-0.67-0.41-0.35-0.06-0.44-1.42
Net Assets From Acquisitions0.000.000.000.000.000.000.003.12-
Sale of Fixed Assets and Businesses0.000.000.000.000.000.010.020.080.00
Purchase or Sale of Investments-13.14-12.94-1.7447.12-45.7510.0913.0614.2124.81
Purchase of Investments-33.60-14.94-8.76-16.40-53.410.000.000.00-0.01
Sale Or Maturity of Investments20.462.007.0263.537.6710.0913.0614.2124.82
Other Uses0.000.000.000.000.000.000.00-0.02-11.58
Other Sources0.000.000.000.000.000.000.020.000.00
Cash from Investing Activities-13.71-13.46-2.3146.45-46.169.7413.0416.9611.82
Cash Dividends Paid0.000.000.000.000.000.000.000.000.00
Change in Capital Stock32.3427.0235.936.511.6837.004.770.065.96
Repurchase of Common Pref Stock0.000.000.000.000.000.000.000.00-0.04
Sale of Common Pref Stock32.3427.0235.936.511.6837.004.770.066.00
Proceedsfrom Stock Options25.1425.4635.706.430.0429.764.770.066.00
Issuance or Reduction of Debt, Net-0.05-0.06-0.05-0.05-0.03-0.0224.60-0.10-0.35
Change in Long Term Debt-0.05-0.06-0.05-0.05-0.03-0.0224.60-0.10-0.35
Issuance of Long Term Debt0.000.000.000.000.000.0024.620.000.00
Reduction of Long Term Debt-0.05-0.06-0.05-0.05-0.03-0.02-0.03-0.10-0.35
Net Financing Active Other Cash Flow-0.04-0.02-0.02-0.04-0.02-0.050.500.650.16
Other Financing Activities Uses-0.04-0.02-0.02-0.04-0.02-0.05-0.03-0.11-0.20
Cash from Financing Activities32.2426.9535.866.421.6336.9329.860.625.77
Exchange Rate Effect0.430.40-0.10-0.25-0.87-0.02-0.060.070.01
Net Change in Cash-4.86-5.0310.3624.06-44.3423.0923.09-14.30-13.29
Free Cash Flow-24.39-19.44-23.66-29.240.65-23.91-19.82-32.39-32.30
Preferred Dividends (Cash Flow)-0.000.000.000.000.000.000.000.00
Price to Free Cash Flow----307.52----
Deferred Taxes & Investment Tax Credit--5.280.00-1.800.000.000.000.000.00

Balance sheet, quarterly

Currency USD, millions
Metric2026Q22026Q12025Q42025Q32025Q22025Q1
Cash & Short Term Investments50.8353.3855.7840.4942.2947.91
Short Term Receivables0.791.391.560.680.260.21
Inventories0.000.000.000.000.000.00
Other Current Assets1.351.391.811.101.301.87
Total Current Assets52.9756.1659.1642.2643.8449.98
Net Property, Plant & Equipment4.484.624.704.474.074.05
Total Investments and Advances0.560.540.530.510.500.46
Intangible Assets42.3742.3742.3742.3742.3757.21
Deferred Tax Assets5.805.805.80---
Other Assets0.040.040.030.030.010.05
Total Assets106.22109.53112.5889.6490.80111.75
Short Term Debt Incl. Current Port. of LT Debt0.950.860.851.071.051.18
Accounts Payable1.541.592.341.521.502.00
Other Current Liabilities5.535.698.176.808.219.91
Total Current Liabilities8.028.1511.379.3810.7613.09
Long Term Debt1.351.531.571.551.111.06
Provision for Risks Charges0.000.000.000.000.000.00
Deferred Tax Liabilities0.020.020.020.270.270.27
Other Liabilities37.0447.1456.2857.6331.5519.67
Total Liabilities46.4256.8469.2468.8443.6934.10
Non-Equity Reserves0.000.000.000.000.000.00
Preferred Stock - Carrying Value0.000.000.000.000.000.00
Common Equity60.9253.8844.5522.0448.3879.03
Total Shareholders Equity60.9253.8844.5522.0448.3879.03
Accumulated Minority Interest-1.12-1.18-1.20-1.24-1.27-1.37
Total Equity59.8052.7043.3520.8047.1177.66
Total Liabilities & Stockholders Equity106.22109.53112.5889.6490.80111.75
Book Value Per Share0.240.220.180.100.210.35
Tangible Book Value Per Share0.070.050.01-0.090.030.10
Full-Time Employees--77---
Price to Book Ratio4.327.3117.457.982.621.27
Return on Assets-32.75-58.03-56.27-72.66-42.26-14.72
Return on Equity-59.03-96.62-103.36-153.37-70.12-21.40
Return on Invested Capital2.38-8.691.85-126.22-61.55-5.17
Quick Ratio6.616.895.204.504.083.82
Current Ratio6.616.895.204.504.083.82

Cash flow, quarterly

Currency USD, millions
Metric2026Q22026Q12025Q42025Q32025Q22025Q1
Net Income1.48-4.810.85-29.78-30.46-4.14
Depreciation0.190.190.190.180.170.16
Other Funds (Non Cash)-8.55-1.34-0.7227.5627.11-0.64
Funds from Operations-6.88-5.96-4.96-2.04-3.19-4.62
Extraordinary Item0.000.000.000.000.000.00
Changes in Working Capital-0.37-2.120.08-1.57-2.35-0.27
Cash from Operating Activities-7.24-8.08-4.88-3.62-5.54-4.89
Capital Expenditures-0.11-0.06-0.40-0.01-0.01-0.10
Net Assets From Acquisitions0.000.000.000.000.000.00
Sale of Fixed Assets and Businesses0.000.000.000.000.000.00
Purchase or Sale of Investments4.07-2.27-14.940.000.002.00
Purchase of Investments-10.43-8.24-14.940.000.000.00
Sale Or Maturity of Investments14.495.960.000.000.002.00
Other Uses0.000.000.000.000.000.00
Other Sources0.000.000.000.000.000.00
Cash from Investing Activities3.96-2.33-15.33-0.01-0.011.90
Cash Dividends Paid0.000.000.000.000.000.00
Preferred Dividends (Cash Flow)0.000.000.000.000.000.00
Change in Capital Stock4.475.6220.391.85-0.295.07
Repurchase of Common Pref Stock0.000.000.000.000.000.00
Sale of Common Pref Stock4.475.6220.391.85-0.295.07
Proceedsfrom Stock Options4.470.0019.631.04-0.295.07
Issuance or Reduction of Debt, Net-0.01-0.01-0.01-0.02-0.01-0.01
Change in Long Term Debt-0.01-0.01-0.01-0.02-0.01-0.01
Issuance of Long Term Debt0.000.000.000.000.000.00
Reduction of Long Term Debt-0.01-0.01-0.01-0.02-0.01-0.01
Net Financing Active Other Cash Flow0.00-0.04-0.000.000.00-0.01
Other Financing Activities Uses0.00-0.04-0.000.000.00-0.01
Cash from Financing Activities4.475.5620.381.83-0.315.04
Exchange Rate Effect0.26-0.010.18-0.000.29-0.07
Net Change in Cash1.44-4.850.35-1.80-5.571.99
Free Cash Flow-7.35-8.13-5.28-3.63-5.55-4.98

Revenue breakdown

Collaboration Revenues2024: 8.15M 2025: 13.61M
Royalties, License and Other Revenues2024: 1.35M 2025: 947.00K
United States2024: 9.50M 2025: 14.56M

Short interest

shares short against float, oldest to newest
SettlementOf floatShares shortFloatAvg volume
2026-10-3012.74%24.3M191.1M1.24M
2026-10-1513.57%25.9M191.1M1.22M
2026-09-3015.30%29.1M190.2M1.11M
2026-09-1515.50%29.5M190.2M1.35M
2026-08-3115.24%29.0M190.2M1.34M
2026-08-1414.90%28.3M190.2M1.38M
2026-07-3115.55%29.6M190.2M1.50M
2026-07-1515.93%29.9M187.5M1.52M
2026-06-3015.04%28.2M187.5M1.53M
2026-06-1513.63%25.6M187.5M1.18M
2026-05-2913.92%26.1M187.4M1.22M
2026-05-1513.83%25.9M187.4M1.21M
2026-04-3013.70%25.6M186.8M1.18M
2026-04-1510.75%25.3M235.3M1.16M
2026-03-3110.83%25.5M235.3M1.16M
2026-03-1310.82%25.5M235.3M1.21M
2026-02-2710.65%25.1M235.3M1.18M
2026-02-1311.58%25.2M217.6M1.25M
2026-01-3011.65%25.3M217.6M1.58M
2026-01-1511.54%25.1M217.6M1.69M

Option chain

expiry 2026-11-20
TypeStrikeBidAskLastIVOpen intVolumeDeltaThetaVega
call0.500.151.100.0031.5220.000.000.899-0.0120.000
call1.000.000.900.0516.0671160.000.690-0.0080.001
call1.500.000.050.012.47213.000.000.242-0.0070.001
call2.000.000.050.003.4750.000.000.194-0.0080.000
call2.500.000.300.004.0790.000.000.171-0.0100.000
call5.000.001.000.006.0720.000.000.134-0.0130.000
call7.500.001.000.007.0980.000.000.123-0.0140.000
put0.500.000.300.006.9300.000.00-0.101-0.0120.000
put1.000.000.100.1514.6862010.00-0.092-0.0240.000
put1.500.051.000.0010.9520.000.00-0.750-0.0070.001
put2.000.501.450.8511.2581.000.00-0.805-0.0090.000
put2.501.001.900.0011.3160.000.00-0.829-0.0100.000
put5.003.504.500.0015.0870.000.00-0.865-0.0120.000
put7.506.007.000.0016.2510.000.00-0.877-0.0130.000

Latest SEC filings

30
FiledFormDescriptionPeriodLink
2026-08-0610-QQuarterly report pursuant to Section 13 or 15(d)2026-06-30SEC
2026-08-068-KCurrent report2026-08-06SEC
2026-07-29SCHEDULE 13GSEC
2026-07-024Statement of changes in beneficial ownership of securities2026-07-01SEC
2026-07-024Statement of changes in beneficial ownership of securities2026-07-01SEC
2026-07-024Statement of changes in beneficial ownership of securities2026-07-01SEC
2026-07-024Statement of changes in beneficial ownership of securities2026-07-01SEC
2026-07-024Statement of changes in beneficial ownership of securities2026-07-01SEC
2026-07-024Statement of changes in beneficial ownership of securities2026-07-01SEC
2026-06-128-KCurrent report2026-06-09SEC
2026-05-1210-QQuarterly report pursuant to Section 13 or 15(d)2026-03-31SEC
2026-05-128-KCurrent report2026-05-12SEC
2026-04-29ARSAnnual report to security holders. 2025-12-31SEC
2026-04-29DEFA14AProxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934SEC
2026-04-29DEF 14AProxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 19342026-04-29SEC
2026-03-23EFFECTEffectiveness filing by commission orderSEC
2026-03-19CORRESPSEC
2026-03-16UPLOADUpload SubmissionSEC
2026-03-124Statement of changes in beneficial ownership of securities2026-03-12SEC
2026-03-11S-3Registration statement for specified transactions by certain issuers including face-amount certificate companiesSEC
2026-03-118-KCurrent report2026-03-11SEC
2026-03-11424B5SEC
2026-03-064Statement of changes in beneficial ownership of securities2026-03-05SEC
2026-03-064Statement of changes in beneficial ownership of securities2026-03-05SEC
2026-03-064Statement of changes in beneficial ownership of securities2026-03-05SEC
2026-03-0510-KAnnual report pursuant to Section 13 or 15(d)2025-12-31SEC
2026-03-058-KCurrent report2026-03-05SEC
2026-02-134Statement of changes in beneficial ownership of securities2026-02-11SEC
2026-02-134Statement of changes in beneficial ownership of securities2026-02-11SEC
2025-12-194Statement of changes in beneficial ownership of securities2025-12-19SEC

Insider activity by month

MonthBoughtBuysSoldSells
2026-110000
2026-100000
2026-090000
2026-080000
2026-070000
2026-060000
2026-050000
2026-040000
2026-0324.38K100
2026-020000
2026-010000
2025-120000
2025-110000

Institutional holders

Manager% owned
BROADWOOD CAPITAL INC19.88%
BlackRock, Inc.5.29%
VANGUARD CAPITAL MANAGEMENT LLC3.63%
Defender Capital, LLC.2.63%
GEODE CAPITAL MANAGEMENT, LLC2.11%
RAFFLES ASSOCIATES LP2.08%
FIFTH THIRD BANCORP1.94%
MILLENNIUM MANAGEMENT LLC1.21%
STATE STREET CORP0.93%
VANGUARD FIDUCIARY TRUST CO0.67%

Funds

Fund% owned
VANGUARD TOTAL STOCK MARKET INDEX FUND2.37%
iShares Russell 2000 ETF1.67%
VANGUARD EXTENDED MARKET INDEX FUND1.19%
Fidelity Small Cap Index Fund0.80%
iShares Russell 2000 Growth ETF0.69%
iShares Biotechnology ETF0.53%
Fidelity Extended Market Index Fund0.50%
VANGUARD RUSSELL 2000 INDEX FUND0.42%
iShares Micro-Cap ETF0.25%
Schwab Small-Cap Index Fund0.18%

OakChart. LCTX. Cached 15 minutes.